Associated Genetic Biomarkers
XRCC6 is altered in 1.12% of all cancers with colon adenocarcinoma, melanoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in XRCC6 are XRCC6 Mutation (0.98%), XRCC6 T334A (0.07%), XRCC6 Amplification (0.06%), XRCC6 Fusion (0.03%), and XRCC6 G191S (0.03%) .
XRCC6 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain XRCC6 status as an inclusion criterion, 2 are phase 2 (2 open).
Trials with XRCC6 status in the inclusion eligibility criteria most commonly target melanoma and urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is XRCC6 Mutation .
Nivolumab, olaparib, and talazoparib are the most frequent therapies in trials with XRCC6 as an inclusion criteria .
Significance of XRCC6 in Diseases
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.